Acorah Software Products - Accounts Production 16.1.300 false true 31 May 2023 13 May 2022 false true No description of principal activity 1 June 2023 31 October 2024 31 October 2024 14106227 Mrs Leyla Hannbeck iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 14106227 2023-05-31 14106227 2024-10-31 14106227 2023-06-01 2024-10-31 14106227 frs-core:CurrentFinancialInstruments 2024-10-31 14106227 frs-bus:PrivateLimitedCompanyLtd 2023-06-01 2024-10-31 14106227 frs-bus:FilletedAccounts 2023-06-01 2024-10-31 14106227 frs-bus:Micro-entities 2023-06-01 2024-10-31 14106227 frs-bus:AuditExempt-NoAccountantsReport 2023-06-01 2024-10-31 14106227 frs-bus:Director1 2023-06-01 2024-10-31 14106227 2022-05-12 14106227 2023-05-31 14106227 2022-05-13 2023-05-31 14106227 frs-core:CurrentFinancialInstruments 2023-05-31
Registered number: 14106227
Reprise Pharmaceuticals Limited
Financial Statements
For the Period 1 June 2023 to 31 October 2024
Balance Sheet
Registered number: 14106227
31 October 2024 31 May 2023
£ £
Current assets 940 400
Creditors: Amounts Falling Due Within One Year (768 ) (300 )
NET CURRENT ASSETS 172 100
TOTAL ASSETS LESS CURRENT LIABILITIES 172 100
Accruals and deferred income (360 ) (360 )
NET LIABILITIES (188 ) (260 )
CAPITAL AND RESERVES (188 ) (260 )

Notes

1. General Information
Reprise Pharmaceuticals Limited is a private company, limited by shares, incorporated in England & Wales, registered number 14106227 . The registered office is 16 Pondfield Crescent, St Albans, Hertfordshire, AL4 9PF.
2. Average Number of Employees
Average number of employees, including directors, during the period was: NIL (2023: NIL)
- -
For the period ending 31 October 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
On behalf of the board
Mrs Leyla Hannbeck
Director
10/03/2025